Femasys Q3 Revenue Falls 44.5% After $30M Raise

Femasys Inc. (NASDAQ: FEMY) reported third-quarter 2026 sales of $404,597 on 13 November 2026, a decline of $324,797 or 44.5% from $729,394 a year earlier, while U.S. sales edged up to $347,039 from $336,594. The Atlanta-based biomedical company also disclosed a $30 million private placement closed in mid-August and a net loss of $4,564,815, or $0.53 per basic and diluted share, for the quarter ended 30 September 2026.

Context — why the Femasys revenue drop matters now

The headline sales decline was not a demand problem in the company's home market. U.S. sales rose modestly year over year, and the company attributed the overall drop to the timing of international FemBloc orders, which it said follow distributors' customary bulk-ordering practices. Distributors are working through existing inventory to support FemBloc post-market studies, with reorders expected only after those studies finish.

That distinction matters because Femasys is mid-transition from a development-stage story to a commercial one. The company said it kept a lean team and tightly managed resources while it prioritized financing from long-term institutional investors, and it called the mid-August close of the $30 million raise "an important turning point."

The financing was sized to build out a U.S. commercial team, following recent availability of the FemaSeed fertility portfolio to OB/GYNs, and to fund the FemBloc pivotal trial needed for U.S. approval. Femasys framed the strategy around U.S. fertility rates at historic lows and the argument that treatment belongs in the OB/GYN office where women already seek care.

The macro backdrop for small-cap medtech remains rate-sensitive. Higher-for-longer financing costs weigh on pre-profit companies that depend on equity issuance, which is why the placement's timing and terms carry weight for FEMY holders. The company did not disclose the placement's pricing or investor identities in the report.

Data — what the numbers show

The quarterly comparison is stark at the top line and narrower underneath. Total Q3 sales fell 44.5% to $404,597 from $729,394, while U.S. sales rose 3.1% to $347,039 from $336,594. Cost of sales excluding depreciation fell to $187,496 from $293,838.

Metric (Q3)	2026	2025	Change
Total sales	$404,597	$729,394	-44.5%
U.S. sales	$347,039	$336,594	+3.1%
R&D expense	$1,942,927	$1,382,022	+40.6%
Sales and marketing	$943,002	$1,143,805	-17.6%
Net loss	$4,564,815	$4,194,821	wider
Loss per share	$0.53	$2.05	narrower

Research and development rose $560,905, or 40.6%, to $1,942,927, which the company tied to the transition of development products into inventory during 2025 plus higher clinical and compensation costs in 2026. Sales and marketing fell to $943,002 from $1,143,805, consistent with the pre-financing hiring freeze the company described.

Across the nine months to 30 September 2026, total sales fell 21.5% to $1,161,313 from $1,479,926, again on international FemBloc order timing, while U.S. sales rose to $1,038,997 from $1,015,168. Nine-month R&D declined 9.8% to $5,199,206. The nine-month net loss narrowed to $8,187,810, or $1.59 per share, from $14,677,582, or $9.25 per share.

The per-share gap between the two years reflects share count, not profitability. Weighted-average shares and pre-funded warrants outstanding rose to 8,660,381 in Q3 2026 from 2,050,761 a year earlier, following the financing and prior warrant activity.

Analysis — what it means for markets and medtech peers

Femasys sits in the small-cap women's-health device niche, where the comparable set is thin and capital access is the binding constraint. The $30 million placement, with potential total proceeds of up to $85 million if warrants are exercised for cash in full, moved cash and cash equivalents to roughly $23.9 million at 30 September 2026 from $9,266,353 at 31 December 2025.

The balance-sheet repair is visible on the liability side too. Conversion option liability fell to zero from $2,014,000 at year-end, and warrants liabilities fell to zero from $4,943,000, while the warrants line within equity rose to $19,023,695 from $5,246,150. Total stockholders' equity climbed to $27,028,162 from $5,869,302.

The counter-argument is dilution and accumulated deficit. The company carried an accumulated deficit of roughly $154.0 million, and the warrant overhang means future cash exercises would add shares. A reader weighing the equity story has to hold the commercial build-out against that.

Positioning follows the financing. Long-term institutional investors who anchored the placement now hold a stake tied to commercial execution, while the stock's float expanded materially versus a year ago. The company said it has been recruiting commercial professionals with OB/GYN relationships, and that healthcare system partnerships and initial sales achieved with limited resources demonstrate commercial potential.

Outlook — what to watch next

The near-term catalysts are operational. Femasys said the number of actively enrolling sites in the FINALE pivotal trial doubled to twelve, and that it received FDA approval of a modular premarket approval submission approach for FemBloc. Progress on enrollment and any modular PMA milestones are the items to track against the U.S. approval path.

On the commercial side, watch for reorders from international FemBloc distributors once post-market studies complete, since the company attributes the sales decline to that timing rather than lost demand. The report gives no date for those reorders, so the signal to watch is the next quarterly sales split between U.S. and international.

Partnership announcements are the other thread. The company disclosed tie-ups with UNC Health, Minnesota Women's Care, CapexMD for patient financing and SandsRx Pharmacy for medications supporting treatment timing. New system partnerships or territory hires would extend the build-out the placement funded.

Frequently Asked Questions

Why did Femasys revenue fall in Q3 2026?

Total sales fell 44.5% to $404,597 because international FemBloc orders did not repeat at prior levels. The company said distributors were drawing down existing inventory to support FemBloc post-market studies, and that reorders are expected after those studies complete. U.S. sales, by contrast, rose slightly to $347,039 from $336,594, so the decline was concentrated outside the home market.

How much cash does Femasys have after the $30 million raise?

Cash and cash equivalents were approximately $23.9 million at 30 September 2026, up from $9,266,353 at 31 December 2025. The $30 million private placement closed in mid-August 2026, and the company said potential total proceeds could reach up to $85 million if warrants are exercised for cash in full. Femasys also reported an accumulated deficit of roughly $154.0 million.

What is the FemBloc regulatory path in the U.S.?

FemBloc is Femasys' non-surgical, in-office permanent birth control candidate, being advanced through the ongoing FINALE pivotal trial. The company said the FDA approved a modular premarket approval submission approach, and that actively enrolling sites doubled to twelve. FemBloc already received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through partnerships in select international markets.

Bottom Line

Femasys' U.S. sales grew slightly while total revenue fell on order timing, and the $30 million raise now funds the commercial test.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.